12-Week Effectiveness and Safety of Low-Density Lipoprotein Cholesterol-Lowering Therapy by Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition in Patients With Familial Hypercholesterolemia and Hypercholesterolemia　― Data From a Real-World Observational Study of Evolocumab in Japan ―

Background: Evolocumab is the first monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9) approved in Japan for the treatment of patients with familial hypercholesterolemia (FH) and hypercholesterolemia (HC). This study assessed the 12-week effectiveness and safety of low...

Descripción completa

Detalles Bibliográficos
Autores principales: Yokote, Koutaro, Ako, Junya, Kitagawa, Kazuo, Inomata, Hyoe, Sugioka, Toshihiko, Asao, Keiko, Shinmura, Yasuhiko, Shimauchi, Junichiro, Teramoto, Tamio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Circulation Society 2019
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7889485/
https://www.ncbi.nlm.nih.gov/pubmed/33693141
http://dx.doi.org/10.1253/circrep.CR-19-0027

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7889485/
https://www.ncbi.nlm.nih.gov/pubmed/33693141
http://dx.doi.org/10.1253/circrep.CR-19-0027

Ejemplares similares